Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Fan Bu *Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.ORCID 0000-0002-6965-3072
Gang Ye *Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.ORCID 0000-0001-6034-2174
Kiran L Sharma *Center for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Bruno La Rosa *National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Murugesan PalaniappanCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Martin M MatzukCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-1445-8632
Damian W YoungCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-1595-9658
Hailey Turner-HubbardDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.
Katalin TothDepartment of Chemistry, University of Florida Scripps Institute, Jupiter, FL, USA.
Michael CameronDepartment of Chemistry, University of Florida Scripps Institute, Jupiter, FL, USA.ORCID 0000-0003-3154-4775
Robert DaveyNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA. radavey@bu.edu.ORCID 0000-0001-9168-2892
Srinivas ChamakuriCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA. Srinivas.Chamakuri@bcm.edu.ORCID 0000-0002-7586-4992
Peter DosaInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. pidosa@umn.edu.ORCID 0000-0002-0081-3867
Fang LiDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA. lifang@umn.edu.ORCID 0000-0002-1958-366X
Funding
Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Donghoon Chung · 2022 to 2026
$100.9M
Discovery and Development of Small-molecule Direct-acting Antivirals Targeting Ebola and Sudan FilovirusesR01AI195592 · NIAID · UNIVERSITY OF MINNESOTA · PI Peter I Dosa, Fang Li · 2026 to 2026
$790k
NIAID NIH HHS R01 AI195592NIAID NIH HHS U19 AI171954U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI195592U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI171954
6 · The paper itself
Abstract
Ebola virus (EBOV) causes outbreaks with high fatality rates, yet potent small-molecule inhibitors targeting EBOV glycoprotein (GP) remain limited. Here, using DNA-encoded chemical libraries, we screen 4.73 billion compounds against EBOV GP and, through stereochemical optimization, identify MWAC-3634. This compound binds GP with high affinity (K
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A small molecule inhibits Ebola virus entry through glycoprotein stabilization. · full record | OpenQuestion